Stockreport

Immunomedics files U.S. marketing application for sacituzumab govitecan for TNBC [Seeking Alpha]

IMMUNOMEDICS  (IMMU) 
Last immunomedics earnings: 2/27 04:00 pm Check Earnings Report
PDF Immunomedics files U.S. marketing application for sacituzumab govitecan for TNBCImmunomedics (NASDAQ:IMMU)files a U.S. marketing application seeking approval for antibod [Read more]